HONG KONG, Feb. 11 China Cord BloodCorporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider ofcord blood collection, laboratory testing, hematopoietic stem cell processing,and stem cell storage services, today announced that the Securities andExchange Commission ("SEC") declared the Company's registration statementeffective on February 9, 2010. The registration statement relates to theordinary shares underlying warrants and certain other securities issued inconnection with the initial public offering of Pantheon China Acquisition Corp.
As a result of the effectiveness, holders of public warrants issued andoutstanding may now exercise them and receive ordinary shares upon the paymentof the related exercise price.
If you have any questions regarding exercise procedures, please call yourbroker or Continental Stock Transfer & Trust at 212.509.4000 ext. 541.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and the largest cord bloodbanking operator in China in terms of geographical coverage and is the onlycord blood bank operator with more than one license (i.e., Beijing andGuangdong). Under the current PRC government regulations, only one licensedcord blood bank operator is permitted to operate in each licensed region andonly six licenses have been issued as of today. China Cord Blood Corporationprovides cord blood collection, laboratory testing, hematopoietic stem cellprocessing, and stem cell storage services. For more information about ChinaCord Blood Corporation, please visit: http://www.chinacordbloodcorp.com .For more information, please contact: China Cord Blood Corporation Ms. Joeling Law Phone: +852-3605-8180 Email: [email protected]
ICR, Inc. In the United States: Ashley M. Ammon or Christine Duan Phone: +1-646-277-1200 In China: Wei-Jung Yang Phone: +86-10-6599-7968
SOURCE China Cord Blood Corporation